Gynecologic Oncology

New circumstances in Gynecologic Oncology have pushed us to introduce new educational programs that meet the real needs of experienced professionals, so that they can incorporate new advances into their daily practice"

Gynecologic Oncology has undergone remarkable development in the past few years. Both gynecology and oncology face increasingly complex challenges due to the development of diagnostic and therapeutic techniques. Professionals must also get to grips with technological and IT innovations and the use of biomaterials and new, much more conservative surgical procedures.

These developments force specialists to constantly update their knowledge and understanding, by studying the available evidence and developing new skills. This allows them to keep up with technological and social changes to improve patient healthcare.

The Professional Master’s Degree in Gynecologic Oncology allows the specialist to access this information in a practical way, without sacrificing scientific rigor, adapting the process to their personal and professional needs.

This Professional Master’s Degree in Gynecologic Oncology contains the most complete and up-to-date scientific program on the market”

This Professional Master’s Degreein Gynecologic Oncology contains the most complete and up-to-date scientific program on the market. Its most notable features are:

• More than 80 clinical cases, recorded with POV (Point of View) systems from different angles, presented by experts in gynecology and other disciplines: Their graphic, schematic, and eminently practical contents providing scientific and practical information on the disciplines that are essential for professional practice
• The presentation of practical workshops on procedures and techniques
• An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the program
• Action protocols and clinical practice guidelines, which cover the most important modern developments in this specialist area
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and assignments for individual reflection
• Special emphasis on test-based medicine and research methodologies in surgical procedures
• Content that is accessible from any fixed or portable device with an Internet connection

This Professional Master’s Degree may be the best investment you can make when selecting a refresher program for two reasons: in addition to updating your knowledge in Gynecologic Oncology, you will obtain a Professional Master’s Degree from TECH Technological University"

The teaching staff comprises a team of renowned health professionals who bring their professional experience to the program, in addition to recognized specialists belonging to leading scientific societies.

The multimedia content developed with the latest educational technology will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive program to prepare for real situations.

This program is designed around Problem-Based Learning, whereby the professional must try to solve the different professional practice situations that arise throughout the program. To do this, they will be assisted by an innovative, interactive video system created by renowned and experienced experts in the field of gynecology and oncology with extensive teaching experience.

Increase your decision-making confidence by updating your knowledge with this Professional Master’s Degree"

Improve your medical-surgical practice in Gynecologic Oncology with this targeted program"

The syllabus has been designed by a team of professionals aware of the importance of medical education in Gynecologic Oncology and who are committed to excellent teaching using new educational technologies.

This Professional Master’s Degree will allow you to learn about the latest advances in Gynecologic Oncology using the latest educational technology"

Module 1. Biological Principles of Cancer

1.1. Cell Growth Regulation
1.2. Carcinogenesis and Carcinogens
1.3. Genetics of Cancer
1.4. Mechanisms of Apoptosis and Programmed Cell Death
1.5. Molecular Mechanisms of Cancer Production and Metastasis
1.6. Origin of Genetic Alterations
1.7. Epigenetic Changes and Oncogenes
1.8. Angiogenesis

Module 2. Principles of Chemotherapy, Adverse Effects and New Therapies

2.1. Introduction
2.2. Justification for the Use of Chemotherapy
2.3. Development of Cancer and the Influence of Chemotherapy

2.3.1. Tumor Growth
2.3.2. Cellular Cycle
2.3.3. Specific Drugs for Each of the Cellular Phases

2.4. Factors that Influence Treatment

2.4.1. Tumor Characteristics
2.4.2. Patient Tolerance
2.4.3. Treatment Objectives
2.4.4. Pharmacological Factors and Administration Routes

2.5. Principles of Drug Resistance
2.6. Combined Therapies
2.7. Treatment or Dose Adjustments
2.8. Drug Toxicity
2.9. General Management of Chemotherapy Side Effects and Complications
2.10. Antineoplastic Agents in Gynecology

2.10.1. Alkylating Agents
2.10.2. Antibiotics
2.10.3. Antimetabolites
2.10.4. Plant Alkaloids
2.10.5. Topoisomerase 1 Inhibitors
2.10.6. Antiangiogenic Drugs
2.10.7. PARP Inhibitors
2.10.8. Tyrosine Kinase Inhibitors
2.10.9. Other Drugs

2.11. Future Indications

Module 3. Endometrial Cancer I

3.1. Epidemiology and Etiopathogenesis
3.2. Precancerous Lesions
3.3. Hereditary Carcinoma
3.4. Anatomical Pathology and Different Types of Tumors
3.5. Diagnostic Process
3.6. Imaging Tests, Tumor Markers and Possible Screening
3.7. Molecular Diagnostic Tests
3.8. FIGO Classification and Others

Module 4. Endometrial Cancer II

4.1. Introduction
4.2. General Aspects of Surgical Treatment
4.3. Low-Risk Tumors (Stage I, Grade 1)
4.4. High-Risk Tumors (Grade 2-3, Serous or Clear Cells)
4.5. Laparotomy vs. Laparoscopy
4.6. Introduction of Robotic Surgery
4.7. Surgical Technique for High-Risk Tumors
4.8. Adjuvant Treatment

4.8.1. Observation without Additional Treatment

4.8.1.1. Low-Risk, Early-Stage, Low-Grade

4.8.2. Adjuvant Radiotherapy

4.8.2.1. Early-Stage, Intermediate and High-Risk
4.8.2.2. Advanced Stages

4.8.3. Adjuvant Chemotherapy
4.8.4. Peculiarities of Serous and Clear Cell Carcinoma

4.9. Hormonal Treatment
4.10. Recurrent Endometrial Cancer

4.10.1. Surgical Management
4.10.2. Radiotherapy
4.10.3. Chemotherapy

4.11. Endometrial Cancer Monitoring
4.12. Prognosis

Module 5. Cervical Cancer I

5.1. Epidemiology and Etiopathogenesis of the Disease
5.2. Precancerous Lesions and the Evolutionary Process
5.3. Risk Factors for Contracting the Disease
5.4. Notions about Cervical Pathology and HPV
5.5. Normal Colposcopy and Vulvoscopy
5.6. Abnormal Colposcopy and Vulvoscopy
5.7. Cervical Cancer Screening
5.8. Hereditary Carcinoma
5.9. Forms of Presentation in Anatomical Pathology
5.10. Diagnostic Process: Imaging Tests and Tumor Markers
5.11. Role of New Technologies such as PET-CT
5.12. FIGO and TNM Classification for Cervical Carcinoma

Module 6. Cervical Cancer II

6.1. Treatment of Cervical Intraepithelial Neoplasia (CIN)

6.1.1. CIN Surgery
6.1.2. CIN Immunotherapy

6.2. Treatment of Invasive Cervical Cancer

6.2.1. Radical Hysterectomy with Nerve Preservation
6.2.2. Less Radical Hysterectomy
6.2.3. Radical Endoscopic Hysterectomy
6.2.4. Selective Sentinel Node Biopsy
6.2.5. Para-Aortic Advanced Stage Lymphadenectomy Staging

6.3. Radiotherapy and Chemotherapy

6.3.1. Concurrent Chemoradiotherapy
6.3.2. Enhanced Forms of Radiotherapy
6.3.3. Forms of Chemotherapy for Concurrent Treatment
6.3.4. Preoperative Chemoradiotherapy
6.3.5. Adjuvant Therapy after a Radical Hysterectomy
6.3.6. Neoadjuvant Chemotherapy
6.3.7. Adjuvant Therapy after Neoadjuvant and Previous Surgery

6.4. Treatment of Metastasis, Recurrent or Persistent Disease

6.4.1. Surgical Management
6.4.2. Chemotherapy

6.5. Management of Cervical Adenocarcinoma

6.5.1. Adenocarcinoma in Situ (AIS)
6.5.2. Comparison between Squamous Cell Carcinomas and Adenocarcinomas
6.5.3. Surgery vs. Radiotherapy in Invasive Adenocarcinoma
6.5.4. Chemotherapy

6.6. Monitoring

Module 7. Ovarian Cancer I

7.1. Epidemiology of Ovarian and Fallopian Tube Cancer
7.2. Etiopathogenesis and Tubal Origin, New Trends
7.3. Precancerous Lesions in the Fallopian Tubes
7.4. Ovarian Cancer Screening
7.5. Hereditary Carcinoma and How to Evaluate It
7.6. Histological Forms and Pathological Anatomy
7.7. Diagnostic Process

7.7.1. Clinical Symptoms
7.7.2. Ultrasound
7.7.3. Computerized Tomography
7.7.4. Magnetic Resonance
7.7.5. Positron Emission Tomography

7.8. Serum Tumor Markers

7.8.1. CA125
7.8.2. HE4
7.8.3. CA19-9
7.8.4. CEA
7.8.5. Other Markers

7.9. FIGO Classification of the Disease

Module 8. Ovarian Cancer II

8.1. General Surgical Treatment
8.2. Complete Cytoreduction and Primary Debulking
8.3. Neoadjuvant Treatment and When to Choose It
8.4. Interval and Second Look Treatments
8.5. Adjuvant Therapy: Carboplatin-Taxol and Other Options
8.6. Radiotherapy: What Role Does It Play?
8.7. Potential Hormonal Therapy for Ovarian Cancer
8.8. Prognosis and Disease-Free Interval
8.9. Monitoring and Treatment of Relapses
8.10. Controversial Issues in the Management of Ovarian Cancer
8.11. Peritoneal Carcinomas: Hyperthermic Therapy
8.12. Intraperitoneal Chemotherapy: Indications and Results

Module 9. Vulvar Cancer I

9.1. Epidemiology and Relationship with HPV
9.2. Etiopathogenesis and Precancerous Lesions
9.3. VIN I, II, III: VAIN and Other Lesions
9.4. Vulvar Cancer Screening
9.5. Hereditary Carcinoma
9.6. Anatomical Pathology and Histological Types
9.7. Imaging Tests and Extension Study
9.8. Tumor Markers: SCC

Module 10. Vulvar Cancer II

10.1. Introduction
10.2. Vulvar Paget’s Disease

10.2.1. General Aspects
10.2.2. Paget’s Disease Type 1

10.2.2.1. Prevalence
10.2.2.2. Clinical Characteristics
10.2.2.3. Diagnosis
10.2.2.4. Treatment

10.2.3. Paget’s Disease Type 2 and 3

10.3. Invasive Paget’s Disease

10.3.1. General Aspects
10.3.2. Prognosis

10.4. Invasive Vulvar Carcinoma

10.4.1. Squamous Cell Carcinoma
10.4.2. Clinical Characteristics
10.4.3. Diagnosis
10.4.4. Dissemination Pathways
10.4.5. Staging
10.4.6. Treatment

10.4.6.1. Primary Lesion Management
10.4.6.2. Local Control after Primary Surgical Treatment
10.4.6.3. Management of Ganglionic Chains
10.4.6.4. Postoperative Care

10.4.6.4.1. Early Postoperative Complications
10.4.6.4.2. Late Postoperative Complications

10.4.6.5. Use of Sentinel Lymph Node

10.4.6.5.1. Advanced Disease
10.4.6.5.2. General Aspects
10.4.6.5.3. Management of Ganglionic Chains
10.4.6.5.4. Primary Tumor Management

10.4.6.5.4.1. Surgery
10.4.6.5.4.2. Radiotherapy
10.4.6.5.4.3. Chemotherapy

10.4.6.6. Role of Radiotherapy in Vulvar Cancer
10.4.7. Recurrent Vulvar Cancer
10.4.8. Prognosis
10.4.9. Monitoring

10.5. Vulvar Melanoma

10.5.1. Introduction
10.5.2. Clinical Characteristics
10.5.3. Pathologic Anatomy
10.5.4. Staging
10.5.5. Treatment

10.5.5.1. Primary Lesion Management
10.5.5.2. Management of Ganglionic Chains

10.5.6. Prognosis

10.6. Bartholin’s Gland Carcinoma

10.6.1. General Aspects
10.6.2. Treatment
10.6.3. Prognosis

10.7. Basal Cell Carcinoma
10.8. Verrucous Carcinoma
10.9. Vulva Sarcoma

10.9.1. Introduction
10.9.2. Leiomyosarcoma
10.9.3. Epithelioid Sarcoma
10.9.4. Rhabdomyosarcoma
10.9.5. Merkel Cell Carcinoma

Module 11. Uterine Sarcoma I

11.1. Introduction
11.2. Epidemiology

11.2.1. Incidence
11.2.2. Age
11.2.3. Histological Distribution
11.2.4. Racial Distribution

11.3. Risk Factors

11.3.1. Heritage
11.3.2. Hormone Therapy
11.3.3. Radiation Exposure

11.4. Anatomical Pathology

11.4.1. Leiomyosarcoma
11.4.2. STUMP
11.4.3. Benign Metastasizing Leiomyoma
11.4.4. Carcinosarcoma
11.4.5. Endometrial Stromal Neoplasms
11.4.6. Stromal Nodule
11.4.7. Endometrial Stromal Sarcoma
11.4.8. Mullerian Adenosarcoma

11.5. Clinical Manifestations
11.6. Imaging Tests
11.6.1. Magnetic Resonance
11.6.2. Tumor Markers
11.7. FIGO Staging
11.8. Conclusions

Module 12. Uterine Sarcoma II

12.1. Introduction
12.2. Uterine Leiomyosarcoma

12.2.1. Early Stages

12.2.1.1. Surgery
12.2.1.2. Adjuvant Radiotherapy
12.2.1.3. Chemotherapy

12.2.2. Recurrent or Metastatic Disease

12.2.2.1. Surgery
12.2.2.2. Chemotherapy
12.2.2.3. Hormone Therapy

12.2.3. Prognostic Factors

12.3. Endometrial Stromal Sarcoma

12.3.1. Early Stages

12.3.1.1. Surgery
12.3.1.2. Pelvic Radiotherapy
12.3.1.3. Hormone Therapy

12.3.2. Recurrent or Metastatic Disease

12.3.2.1. Surgery
12.3.2.2. Chemotherapy or Radiotherapy

12.3.3. Prognostic Factors

12.4. Undifferentiated Endometrial Sarcoma

12.4.1. Early Stages

12.4.1.1. Surgery
12.4.1.2. Adjuvant Radiotherapy
12.4.1.3. Chemotherapy

12.4.2. Recurrent or Metastatic Disease

12.4.2.1. Surgery
12.4.2.2. Chemotherapy or Radiotherapy

12.4.3. Prognostic Factors

12.5. Conclusions

Module 13. Fertility Preservation

13.1. Indications of Fertility Preservation
13.2. Gametes Preservation
13.3. Role of Assisted Reproduction Techniques
13.4. Conservative Surgical Treatment
13.5. Oncological Prognosis after Fertility Conservation
13.6. Reproductive Results
13.7. Management of Pregnant Women with Gynecologic Cancer
13.8. New Lines of Research and Literature Updates
13.9. Conservation of Ovarian Tissue
13.10. Uterine and Gonadal Tissue Transplantation

Module 14. Rare Gynecologic Tumors

14.1. Vaginal Cancer

14.1.1. Introduction
14.1.2. Clinical Manifestations
14.1.3. Diagnosis
14.1.4. Anatomical Pathology

14.1.4.1. Squamous Carcinoma
14.1.4.2. Adenocarcinoma
14.1.4.3. Sarcoma
14.1.4.4. Melanoma

14.1.5. Tumor Staging
14.1.6. Treatment of Disease

14.1.6.1. Surgery
14.1.6.2. Radiotherapy
14.1.6.3. Treatment Complications

14.1.7. Monitoring
14.1.8. Prognosis

14.2. Gestational Trophoblastic Disease

14.2.1. Introduction and Epidemiology
14.2.2. Clinical Forms

14.2.2.1. Hydatidiform Mole

14.2.2.1.1. Complete Hydatidiform Mole
14.2.2.1.2. Partial Hydatidiform Mole

14.2.2.2. Gestational Trophoblastic Neoplasm

14.2.2.2.1. After Molar Pregnancy

14.2.2.2.1.1. Persistent Gestational Trophoblastic Neoplasm

14.2.2.2.2. After Non-Molar Pregnancy

14.2.2.2.2.1. Choriocarcinoma
14.2.2.2.2.2. Placental Site Trophoblastic Tumor

14.2.3. Diagnosis

14.2.3.1. Human Chorionic Gonadotropin
14.2.3.2. Ultrasound Study

14.2.3.2.1. Complete Mole
14.2.3.2.2. Partial Mole
14.2.3.2.3. Invasive Mole
14.2.3.2.4. Choriocarcinoma and Placental Site Tumor

14.2.3.3. Other Imaging Techniques

14.2.4. Pathologic Anatomy

14.2.4.1. Hydatidiform Mole

14.2.4.1.1. Complete Mole
14.2.4.1.2. Partial Mole

14.2.4.2. Invasive Mole
14.2.4.3. Choriocarcinoma
14.2.4.4. Placental Site Trophoblastic Tumor
14.2.4.5. Epithelioid Trophoblastic Tumor

14.2.5. Staging
14.2.6. Treatment

14.2.6.1. Chemotherapy

14.2.6.1.1. Low-Risk Disease
14.2.6.1.2. High-Risk Disease and Metastasis
14.2.6.1.3. Chemoresistant Disease

14.2.6.2. Surgery

14.2.6.2.1. Molar Evacuation
14.2.6.2.2. Hysterectomy
14.2.6.2.3. Myometrial Resection
14.2.6.2.4. Pulmonary Resection
14.2.6.2.5. Craniotomy
14.2.6.2.6. Other Surgical Procedures
14.2.6.2.7. Selective Arterial Embolization

14.2.7. Post-Treatment Monitoring

14.2.7.1. Monitoring after Molar Evacuation
14.2.7.2. Monitoring after Gestational Neoplasm Treatment

14.2.8. Prognosis

14.3. Metastatic Tumor in the Genital Tract

14.3.1. Introduction
14.3.2. Clinical Manifestations

14.3.2.1. Secondary Tumors in the Uterine Body or Cervix

14.3.2.2.1. Originating from Genital or Pelvic Organs
14.3.2.2.2. Originating from Extragenital or Pelvic Organs

14.3.2.2. Secondary Vaginal Tumors
14.3.2.3. Secondary Vulvar Tumors
14.3.2.4. Secondary Ovarian Tumors

14.3.3. Diagnosis
14.3.4. Anatomical Pathology

14.3.4.1. Gastrointestinal Tumors

14.3.4.1.1. Intestinal Cancer Metastasis
14.3.4.1.2. Krukenberg Tumor

14.3.4.2. Ovarian Lymphoma

14.3.5. Treatment and Prognosis

14.4. Neuroendocrine Tumors

14.4.1. Introduction
14.4.2. Anatomical Pathology

14.4.2.1. Well-Differentiated Tumors
14.4.2.2. Poorly-Differentiated Tumors

14.4.3. Clinical Manifestations and Diagnosis

14.4.3.1. Small Cell Carcinoma of the Vulva and Vagina
14.4.3.2. Small Cell Carcinoma of the Uterus
14.4.3.3. Neuroendocrine Carcinoma of the Cervix

14.4.3.3.1. Small Cell Neuroendocrine Carcinoma
14.4.3.3.2. Large Cell Neuroendocrine Carcinoma

14.4.3.4. Ovarian, Fallopian Tube and Wide Ligament Tumor

14.4.3.4.1. Ovarian Carcinoid Tumor

14.4.3.4.1.1. Insular Carcinoid Tumor
14.4.3.4.1.2. Trabecular Carcinoid Tumor
14.4.3.4.1.3. Mucinous Carcinoid Tumor
14.4.3.4.1.4. Strumal Carcinoid Tumor

14.4.3.4.2. Small Cell Lung Type
14.4.3.4.3. Undifferentiated Non-Small Cell Carcinoma

14.4.4. Treatment
14.4.5. Monitoring
14.4.6. Prognosis

14.5. Rectovaginal Septum Tumors

Module 15. Palliative Care and Nutrition

15.1. Introduction

15.1.1. Symptomology Associated with Gynecologic Tumors

15.2. Pain
15.3. Gastrointestinal Symptoms

15.3.1. Diarrhea
15.3.2. Constipation
15.3.3. Malignant Intestinal Obstruction

15.3.3.1. Conservative Treatment
15.3.3.2. Surgical Management

15.4. Ascites
15.5. Respiratory Symptoms

15.5.1. Pleural Effusion

15.6. Edema
15.7. Anorexia and Weight Loss
15.8. Deep Vein Thrombosis
15.9. Pelvic Disease Progression

15.9.1. Vaginal Bleeding
15.9.2. Fistulas

15.10. Palliative Pelvic Exenteration
15.11. Metastasis to Other Organs

15.11.1. Liver
15.11.2. Brain
15.11.3. Bone

15.11.3.1. Hypercalcemia

15.12. Anxiety and Depression
15.13. Palliative Ca

A unique, key, and decisive Training experience to boost your professional development”